France· FR:65312065
ELREXFIO 40 mg/mL, solution injectable
A elranatamab product containing elranatamab, registered in France by PFIZER EUROPE MA EEIG (BELGIQUE). The same ATC class is registered in 13 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Elranatamab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX32 (elranatamab), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Elranatamab · ATC L01FX32
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ELRANATAMAB
- Manufacturer
- PFIZER EUROPE MA EEIG (BELGIQUE)
- Country
- France (FR)
- ATC code
- L01FX32
- ATC class
- Elranatamab
- Defined daily dose
- 5.43 mg, P
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
- cip1334009550983001 flacon(s) en verre de 1,1 ml
- cip1334009550983171 flacon(s) en verre de 1,9 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Elranatamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesElrexfioPfizer Laboratories Div Pfizer Inc
- IrelandELREXFIO 40 mg/mL solution for injectionPfizer Europe MA EEIG
- NetherlandsELREXFIO 40 mg/ml oplossing voor injectiePfizer Europe MA EEIG
- CanadaELREXFIOPFIZER CANADA ULC
- SwitzerlandElrexfio
- CzechiaELREXFIOPfizer Europe MA EEIG, Bruxelles
- BelgiumElrexfio 40 mg/mlPfizer Europe MA
- United KingdomElrexfio 44mg/1.1ml solution for injection vialsPfizer Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Elrexfio
- Liechtenstein · Elrexfio
- Norway · Elrexfio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/355941f1-4088-4610-b556-4bb42bc3b249 GET /v1/drugs/355941f1-4088-4610-b556-4bb42bc3b249?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "65312065",
"date_amm": "2023-12-07",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/23/1770",
"substance": "ELRANATAMAB",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about elranatamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.